作者: E. Uriol , M. Sierra , M. A. Comendador , J. Fra , P. Martínez-Camblor
关键词:
摘要: Most chemotherapy treatments induce DNA damage in the exposed patients. Using comet assay and peripheral blood mononuclear cells (PBMC), we have quantified this induced studied its relationship with GSTM1 GSTT1 polymorphisms, clinical parameters. For purpose, 29 Caucasian women, breast cancer patients under CMF or CEF adjuvant were included study. The parameters considered (i) therapies side effects, like haematological biochemical toxicities, (ii) prognostic predictive factors, hormonal receptor expression, tumour differentiation degree, sickness stage, nodal status, (iii) effectiveness of measured as five years relapse probability. results also related to confounding factor age. Comet indicate that 13 characterised by absence strand breaks, 16 presented breaks along treatment. Relationships between variables parameters, found principal component analysis, correlations, one-way ANOVA multivariate logistic regression analyses revealed that: (1) baseline levels are genotype expression; (2) influences after chemotherapy, it does AST level; (3) tail moment values cycle 6.1 stage might predict at years: for Stage, OR = 13.8 (IIB versus I+IIA), 95% CI 0.80-238.97, TM, 1.3, 95%, 0.97-1.79, a potential model (10* Stage (I-IIA 0, IIB 1) + cycle), has good capacity, an area ROC curve 0.872 (CI 0.62-1.00). To our knowledge, is first time such value assay. Nevertheless, before could be used tool oncologists, should confirmed more patients, problems standardisation data interpretation solved.